Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lee Harland

Showing results (1-10 of 16) with videos related to

Pageof 2
Sort By:
Expert Opinion on Drug Discovery|March 19, 2013
Drug target centralLee Harland, Anna Gaulton
Nature Reviews. Drug Discovery|March 3, 2007
High-throughput electronic biology: mining information for drug discoveryWilliam Loging, Lee Harland, Bryn Williams-Jones
Drug Discovery Today|December 3, 2014
Drug discovery FAQs: workflows for answering multidomain drug discovery questionsChristine Chichester, Daniela Digles, Ronald Siebes, et al.
Genomics|April 12, 2002
Transcriptional regulation of the human TATA binding protein geneLee Harland, Robert Crombie, Simon Anson, et al.
Drug Discovery Today|October 21, 2009
Visualizing the drug target landscapeStephen J Campbell, Anna Gaulton, Jason Marshall, et al.
Drug Discovery Today|December 20, 2011
Visualizing the drug target landscapeStephen J Campbell, Anna Gaulton, Jason Marshall, et al.
Drug Discovery Today|January 7, 2012
Systems chemical biology and the Semantic Web: what they mean for the future of drug discovery researchDavid J Wild, Ying Ding, Amit P Sheth, et al.
Nature Reviews. Drug Discovery|July 18, 2009
Lowering industry firewalls: pre-competitive informatics initiatives in drug discoveryMichael R Barnes, Lee Harland, Steven M Foord, et al.
Nature Reviews. Drug Discovery|February 1, 2014
Precompetitive activity to address the biological data needs of drug discoveryBen Sidders, Christoph Brockel, Alex Gutteridge, et al.
Genomics|August 9, 2003
Transgenes encompassing dual-promoter CpG islands from the human TBP and HNRPA2B1 loci are resistant to heterochromatin-mediated silencingMichael Antoniou, Lee Harland, Tracey Mustoe, et al.
Pageof 2

Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
Expert Opinion on Drug Discovery|March 19, 2013
Drug target centralLee Harland, Anna Gaulton
Nature Reviews. Drug Discovery|March 3, 2007
High-throughput electronic biology: mining information for drug discoveryWilliam Loging, Lee Harland, Bryn Williams-Jones
Drug Discovery Today|December 3, 2014
Drug discovery FAQs: workflows for answering multidomain drug discovery questionsChristine Chichester, Daniela Digles, Ronald Siebes, et al.
Genomics|April 12, 2002
Transcriptional regulation of the human TATA binding protein geneLee Harland, Robert Crombie, Simon Anson, et al.
Drug Discovery Today|October 21, 2009
Visualizing the drug target landscapeStephen J Campbell, Anna Gaulton, Jason Marshall, et al.
Drug Discovery Today|December 20, 2011
Visualizing the drug target landscapeStephen J Campbell, Anna Gaulton, Jason Marshall, et al.
Drug Discovery Today|January 7, 2012
Systems chemical biology and the Semantic Web: what they mean for the future of drug discovery researchDavid J Wild, Ying Ding, Amit P Sheth, et al.
Nature Reviews. Drug Discovery|July 18, 2009
Lowering industry firewalls: pre-competitive informatics initiatives in drug discoveryMichael R Barnes, Lee Harland, Steven M Foord, et al.
Nature Reviews. Drug Discovery|February 1, 2014
Precompetitive activity to address the biological data needs of drug discoveryBen Sidders, Christoph Brockel, Alex Gutteridge, et al.
Genomics|August 9, 2003
Transgenes encompassing dual-promoter CpG islands from the human TBP and HNRPA2B1 loci are resistant to heterochromatin-mediated silencingMichael Antoniou, Lee Harland, Tracey Mustoe, et al.
Pageof 2